Cargando…

Chemotherapy Response Score in Ovarian Cancer Patients: An Overview of Its Clinical Utility

The chemotherapy response score has been developed over the last few years as a predictive index of survival outcomes for patients with advanced-stage epithelial ovarian cancer undergoing interval debulking surgery. While its importance in predicting patients at risk of developing recurrences earlie...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodolakis, Ioannis, Pergialiotis, Vasilios, Liontos, Michalis, Haidopoulos, Dimitrios, Loutradis, Dimitrios, Rodolakis, Alexandros, Bamias, Aristotelis, Thomakos, Nikolaos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054535/
https://www.ncbi.nlm.nih.gov/pubmed/36983157
http://dx.doi.org/10.3390/jcm12062155
_version_ 1785015694478278656
author Rodolakis, Ioannis
Pergialiotis, Vasilios
Liontos, Michalis
Haidopoulos, Dimitrios
Loutradis, Dimitrios
Rodolakis, Alexandros
Bamias, Aristotelis
Thomakos, Nikolaos
author_facet Rodolakis, Ioannis
Pergialiotis, Vasilios
Liontos, Michalis
Haidopoulos, Dimitrios
Loutradis, Dimitrios
Rodolakis, Alexandros
Bamias, Aristotelis
Thomakos, Nikolaos
author_sort Rodolakis, Ioannis
collection PubMed
description The chemotherapy response score has been developed over the last few years as a predictive index of survival outcomes for patients with advanced-stage epithelial ovarian cancer undergoing interval debulking surgery. While its importance in predicting patients at risk of developing recurrences earlier seems to be important, its accuracy in determining patients with a shorter overall survival remains arbitrary. Moreover, standardization of the actual scoring system that was initially developed as a 6-tiered score and adopted as a 3-tiered score is still needed, as several studies suggest that a 2-tiered system is preferable. Given its actual importance in detecting patients with shorter progression-free survival, research should also focus on the actual predictive value of determining patients with platinum resistance, as a suboptimal patient response to standard neoadjuvant chemotherapy might help determine patients at risk of an earlier recurrence. In the present review, we summarize current knowledge retrieved from studies addressing outcomes related to the chemotherapy response score in epithelial ovarian cancer patients undergoing neoadjuvant chemotherapy and discuss differences in outcome reporting to help provide directions for further research.
format Online
Article
Text
id pubmed-10054535
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100545352023-03-30 Chemotherapy Response Score in Ovarian Cancer Patients: An Overview of Its Clinical Utility Rodolakis, Ioannis Pergialiotis, Vasilios Liontos, Michalis Haidopoulos, Dimitrios Loutradis, Dimitrios Rodolakis, Alexandros Bamias, Aristotelis Thomakos, Nikolaos J Clin Med Communication The chemotherapy response score has been developed over the last few years as a predictive index of survival outcomes for patients with advanced-stage epithelial ovarian cancer undergoing interval debulking surgery. While its importance in predicting patients at risk of developing recurrences earlier seems to be important, its accuracy in determining patients with a shorter overall survival remains arbitrary. Moreover, standardization of the actual scoring system that was initially developed as a 6-tiered score and adopted as a 3-tiered score is still needed, as several studies suggest that a 2-tiered system is preferable. Given its actual importance in detecting patients with shorter progression-free survival, research should also focus on the actual predictive value of determining patients with platinum resistance, as a suboptimal patient response to standard neoadjuvant chemotherapy might help determine patients at risk of an earlier recurrence. In the present review, we summarize current knowledge retrieved from studies addressing outcomes related to the chemotherapy response score in epithelial ovarian cancer patients undergoing neoadjuvant chemotherapy and discuss differences in outcome reporting to help provide directions for further research. MDPI 2023-03-10 /pmc/articles/PMC10054535/ /pubmed/36983157 http://dx.doi.org/10.3390/jcm12062155 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Rodolakis, Ioannis
Pergialiotis, Vasilios
Liontos, Michalis
Haidopoulos, Dimitrios
Loutradis, Dimitrios
Rodolakis, Alexandros
Bamias, Aristotelis
Thomakos, Nikolaos
Chemotherapy Response Score in Ovarian Cancer Patients: An Overview of Its Clinical Utility
title Chemotherapy Response Score in Ovarian Cancer Patients: An Overview of Its Clinical Utility
title_full Chemotherapy Response Score in Ovarian Cancer Patients: An Overview of Its Clinical Utility
title_fullStr Chemotherapy Response Score in Ovarian Cancer Patients: An Overview of Its Clinical Utility
title_full_unstemmed Chemotherapy Response Score in Ovarian Cancer Patients: An Overview of Its Clinical Utility
title_short Chemotherapy Response Score in Ovarian Cancer Patients: An Overview of Its Clinical Utility
title_sort chemotherapy response score in ovarian cancer patients: an overview of its clinical utility
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054535/
https://www.ncbi.nlm.nih.gov/pubmed/36983157
http://dx.doi.org/10.3390/jcm12062155
work_keys_str_mv AT rodolakisioannis chemotherapyresponsescoreinovariancancerpatientsanoverviewofitsclinicalutility
AT pergialiotisvasilios chemotherapyresponsescoreinovariancancerpatientsanoverviewofitsclinicalutility
AT liontosmichalis chemotherapyresponsescoreinovariancancerpatientsanoverviewofitsclinicalutility
AT haidopoulosdimitrios chemotherapyresponsescoreinovariancancerpatientsanoverviewofitsclinicalutility
AT loutradisdimitrios chemotherapyresponsescoreinovariancancerpatientsanoverviewofitsclinicalutility
AT rodolakisalexandros chemotherapyresponsescoreinovariancancerpatientsanoverviewofitsclinicalutility
AT bamiasaristotelis chemotherapyresponsescoreinovariancancerpatientsanoverviewofitsclinicalutility
AT thomakosnikolaos chemotherapyresponsescoreinovariancancerpatientsanoverviewofitsclinicalutility